Minimal residual disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:27:10 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Minimal residual disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of Blinatumomab in Children with Relapsed or Treatment-Resistant B Cell Acute Lymphoblastic Leukemia with Remaining Disease Traces https://clinicaltrials.eu/trial/a-study-of-blinatumomab-in-children-with-relapsed-or-treatment-resistant-b-cell-acute-lymphoblastic-leukemia-with-remaining-disease-traces/ Thu, 30 Apr 2026 13:08:36 +0000 https://clinicaltrials.eu/trial/a-study-of-blinatumomab-in-children-with-relapsed-or-treatment-resistant-b-cell-acute-lymphoblastic-leukemia-with-remaining-disease-traces/ This study involves children with B-Cell Precursor Acute Lymphoblastic Leukemia, which is a type of blood cancer that affects white blood cells. The study focuses on two specific situations: when the disease has come back after treatment or has not responded to previous treatments (called relapsed or refractory), and when small amounts of cancer cells remain in the body even after treatment (called minimal residual disease positive). The treatment being tested is blinatumomab, which is given as an injection under the skin. This medication works by helping the body’s immune system find and attack cancer cells.

The purpose of the study is to test how safe and effective this under-the-skin method of giving blinatumomab is in children under 12 years of age, and to see if it can help eliminate cancer cells from the body. The study is divided into different parts. In the first part, doctors will check if the treatment is safe and well-tolerated in young children. In the second part, doctors will measure how well the treatment works by checking if cancer cells disappear from the bone marrow, which is the spongy tissue inside bones where blood cells are made.

During the study, children will receive the medication in treatment cycles, and doctors will regularly check their blood and bone marrow to see how the disease is responding. The study will also measure the levels of medication in the blood to understand how the body processes it, and will check if the body develops any reaction to the medication. Doctors will monitor for any side effects throughout the treatment period and will track how long any positive response to the treatment lasts.

]]>